Sirtris clinical trials
Acquired by GlaxoSmithKline, Jun 2, 2008 · source ↗
The registry lists 13 studies whose lead sponsor is Sirtris. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 27, 2019.
- 13studies on the registry
- 0open to participants now
Before and after it joined GlaxoSmithKline
- First submitted before Sirtris became part of GlaxoSmithKline
- 0
- First submitted after Sirtris became part of GlaxoSmithKline
- 13
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Sirtris’s studies test, most studies first; none is open now — 5 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 13 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 308
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Sirtris, a GSK Company13 studies
Something wrong with this grouping? Tell us on the GlaxoSmithKline page.
Studies
Recruiting first, then most recently updated. Showing 13 of 13. All GlaxoSmithKline studies →
- A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple MyelomaTerminatedNCT00920556Phase 2
Sponsor listed in the registry: Sirtris, a GSK Company · First submitted after Sirtris became part of GlaxoSmithKline
- Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human SubjectsCompletedNCT00937326Phase 2
Sponsor listed in the registry: Sirtris, a GSK Company · First submitted after Sirtris became part of GlaxoSmithKline
- A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic DiseasesCompletedNCT01340911Phase 1
Sponsor listed in the registry: Sirtris, a GSK Company · First submitted after Sirtris became part of GlaxoSmithKline
- Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type PsoriasisCompletedNCT01154101Phase 2
Sponsor listed in the registry: Sirtris, a GSK Company · First submitted after Sirtris became part of GlaxoSmithKline
- Effect of SRT2379 on Endotoxin-Induced InflammationCompletedNCT01262911Phase 1
Sponsor listed in the registry: Sirtris, a GSK Company · First submitted after Sirtris became part of GlaxoSmithKline
- A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy VolunteersCompletedNCT00938275Phase 1
Sponsor listed in the registry: Sirtris, a GSK Company · First submitted after Sirtris became part of GlaxoSmithKline
- A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes MellitusCompletedNCT01031108Phase 1
Sponsor listed in the registry: Sirtris, a GSK Company · First submitted after Sirtris became part of GlaxoSmithKline
- Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced InflammationCompletedNCT01416376Phase 1
Sponsor listed in the registry: Sirtris, a GSK Company · First submitted after Sirtris became part of GlaxoSmithKline
- A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic MetastasesCompletedNCT00920803Phase 1
Sponsor listed in the registry: Sirtris, a GSK Company · First submitted after Sirtris became part of GlaxoSmithKline
- A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male VolunteersCompletedNCT01702493Phase 1
Sponsor listed in the registry: Sirtris, a GSK Company · First submitted after Sirtris became part of GlaxoSmithKline
- A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male SubjectsCompletedNCT00937872Phase 1
Sponsor listed in the registry: Sirtris, a GSK Company · First submitted after Sirtris became part of GlaxoSmithKline
- A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative ColitisCompletedNCT01453491Phase 1
Sponsor listed in the registry: Sirtris, a GSK Company · First submitted after Sirtris became part of GlaxoSmithKline
- A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male VolunteersCompletedNCT00933530Phase 1
Sponsor listed in the registry: Sirtris, a GSK Company · First submitted after Sirtris became part of GlaxoSmithKline